Modern Medicines Series
SGLT2 Inhibitors: What we need to know
Over the first 3 programmes, Professor Cliff Bailey and colleagues provided concise evidence-based guidance to assess the clinical evidence and opportunities offered by sodium-glucose co-transporter-2 (SGLT2) inhibitors in the management of type 2 diabetes and its cardio-renal complications. To watch these programmes on-demand please click here
Programmes 4 & 5: SGLT2 Updates will follow at the end of the year after EASD, ESC and ADA
Professor Cliff Bailey - Emeritus Professor of Clinical Science, Aston University, Birmingham
Will facilitate these update sessions.
For more information and to register your interest click here
These webinars are supported by Boehringer Ingelheim through an unrestricted educational grant:
The content, opinions and statements made in these webinars are those of the presenters and do not necessarily reflect the views of the supporters, editors or editorial board and no liability is accepted for the consequences of any misleading or inaccurate information.